INCLUSION AND EXCLUSION CRITERIA

All patients met the following inclusion criteria. 1. Patients diagnosed with primary gastric adenocarcinoma at stage IIB-IIIC through imaging and endoscopic pathological tissue biopsy (according to the 8th edition of the AJCC TNM Staging Criteria of the International Union Against Cancer (UICC), without concurrent other malignant tumors, without distant organ metastasis, and with R0 resection (no residual tumor visible under either macroscopic or microscopic examination); 2. Received 2-4 cycles of preoperative and postoperative adjuvant chemotherapy, with a total of 6-8 cycles of chemotherapy, all at our hospital (in accordance with the NCCN guidelines and CSCO guidelines); 3. The size of the primary tumor lesion could be measured by CT and MRI, and all underwent postoperative pathological biopsy. 4. Eastern Cooperative Oncology Group(ECOG) performance status ≤1 and able to tolerate chemotherapy; with acceptable liver, kidney, hematologic and cardiopulmonary function; Exclusion criteria: 1. Allergic to chemotherapy drugs or having chemotherapy-related contraindications; having severe symptoms such as infectious diseases, gastrointestinal bleeding, pyloric obstruction or gastrointestinal perforation. 2. Patients who have received radiotherapy, chemotherapy, biological therapy or surgery for other malignant tumors. 3. Patients with incomplete or missing case data, or whose imaging data cannot accurately measure the tumor diameter. This trial complies with the Helsinki Declaration.

Treatment

The P-SOX regimen was as follows: Nab-paclitaxel was administered at a dose of 135 mg/m² by intravenous infusion over 3 hours on day 1, and oxaliplatin was administered at a dose of 85 mg/m² by intravenous infusion over 2–4 hours on day 1. S-1 was orally administered from day 1 to day 14, twice daily, 30 minutes after breakfast and dinner. The dose of S-1 was determined according to body surface area (BSA): 40 mg per administration for BSA <1.25 m², 50 mg per administration for BSA 1.25–1.5 m², and 60 mg

per administration for BSA >1.5 m^2. Each cycle lasted 21 days.The FOLFOX regimen was as follows: Oxaliplatin was administered at a dose of 85 mg/m^2 by intravenous infusion on day 1. Leucovorin was administered at a dose of 200 mg/m^2 by intravenous infusion on day 1, followed by 5-fluorouracil at a dose of 400 mg/m^2 by intravenous bolus and then 2,400 mg/m^2 as a continuous intravenous infusion over 46 hours. The regimen was repeated every 2 weeks.